Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
Edwards Lifesciences (NYSE: EW) has scheduled its Q1 2025 earnings announcement for April 23, 2025, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the quarterly results ending March 31, 2025.
Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will be available live and archived on the company's investor relations website at ir.edwards.com.
Edwards Lifesciences, the global leader in structural heart innovation, focuses on developing breakthrough technologies and maintaining partnerships with healthcare stakeholders to deliver life-changing innovations to patients.
Edwards Lifesciences (NYSE: EW) ha programmato l'annuncio dei risultati del primo trimestre 2025 per il 23 aprile 2025, dopo la chiusura del mercato. La società terrà una conference call alle 17:00 ET per discutere i risultati trimestrali al 31 marzo 2025.
Gli investitori potranno partecipare chiamando il numero (877) 704-2848 o (201) 389-0893. La chiamata sarà disponibile in diretta e in archivio sul sito web delle relazioni con gli investitori all'indirizzo ir.edwards.com.
Edwards Lifesciences, leader mondiale nell'innovazione nel settore cardiaco strutturale, si concentra sullo sviluppo di tecnologie rivoluzionarie e sul mantenimento di partnership con gli operatori sanitari per offrire innovazioni che cambiano la vita dei pazienti.
Edwards Lifesciences (NYSE: EW) ha programado el anuncio de sus resultados del primer trimestre de 2025 para el 23 de abril de 2025, después del cierre del mercado. La empresa realizará una conferencia telefónica a las 5:00 p.m. ET para discutir los resultados trimestrales al 31 de marzo de 2025.
Los inversores pueden participar llamando al (877) 704-2848 o al (201) 389-0893. La llamada estará disponible en vivo y archivada en el sitio web de relaciones con inversores de la empresa en ir.edwards.com.
Edwards Lifesciences, líder mundial en innovación en el corazón estructural, se centra en desarrollar tecnologías revolucionarias y en mantener asociaciones con actores del sector sanitario para ofrecer innovaciones que cambian la vida de los pacientes.
Edwards Lifesciences (NYSE: EW)는 2025년 1분기 실적 발표를 2025년 4월 23일 시장 마감 후로 예정했습니다. 회사는 2025년 3월 31일 마감 분기 실적에 대해 논의하기 위해 동부 표준시 오후 5시에 컨퍼런스 콜을 진행할 예정입니다.
투자자들은 (877) 704-2848 또는 (201) 389-0893으로 전화해 참여할 수 있습니다. 콜은 회사의 투자자 관계 웹사이트 ir.edwards.com에서 생중계 및 녹화본으로 제공됩니다.
Edwards Lifesciences는 구조적 심장 혁신 분야의 글로벌 리더로서 획기적인 기술 개발과 의료 관계자들과의 파트너십 유지를 통해 환자에게 삶을 변화시키는 혁신을 제공하는 데 집중하고 있습니다.
Edwards Lifesciences (NYSE : EW) a programmé l'annonce de ses résultats du premier trimestre 2025 pour le 23 avril 2025, après la clôture du marché. La société tiendra une conférence téléphonique à 17h00 ET pour discuter des résultats trimestriels au 31 mars 2025.
Les investisseurs peuvent participer en appelant le (877) 704-2848 ou le (201) 389-0893. L'appel sera disponible en direct et en archive sur le site des relations investisseurs de la société à ir.edwards.com.
Edwards Lifesciences, leader mondial de l'innovation en cardiologie structurelle, se concentre sur le développement de technologies révolutionnaires et le maintien de partenariats avec les acteurs de la santé afin d'apporter aux patients des innovations qui changent leur vie.
Edwards Lifesciences (NYSE: EW) hat die Bekanntgabe der Ergebnisse für das erste Quartal 2025 für den 23. April 2025 nach Börsenschluss geplant. Das Unternehmen wird um 17:00 Uhr ET eine Telefonkonferenz abhalten, um die Quartalsergebnisse zum 31. März 2025 zu besprechen.
Investoren können teilnehmen, indem sie (877) 704-2848 oder (201) 389-0893 anrufen. Die Telefonkonferenz wird live und als Aufzeichnung auf der Investor-Relations-Website des Unternehmens unter ir.edwards.com verfügbar sein.
Edwards Lifesciences, der weltweit führende Anbieter im Bereich strukturelle Herzinnovationen, konzentriert sich auf die Entwicklung bahnbrechender Technologien und die Pflege von Partnerschaften mit Akteuren im Gesundheitswesen, um lebensverändernde Innovationen für Patienten bereitzustellen.
- None.
- None.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416629009/en/
Media Contact: Amy Hytowitz, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826
Source: Edwards Lifesciences Corporation
FAQ
When will Edwards Lifesciences (EW) release its Q1 2025 earnings?
How can investors join Edwards Lifesciences (EW) Q1 2025 earnings call?
Where can I find Edwards Lifesciences (EW) Q1 2025 earnings call recording?
What period will Edwards Lifesciences (EW) Q1 2025 earnings cover?
